-
Something wrong with this record ?
WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience
V. Valkova, J. Vydra, M. Markova, E. Cerovska, M. Vrana, I. Marinov, H. Cechova, P. Cetkovsky, A. Vitek, C. Salek
Language English Country United States
Document type Journal Article
- MeSH
- Leukemia, Myeloid, Acute blood genetics mortality therapy MeSH
- Adult MeSH
- Risk Assessment methods MeSH
- Incidence MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local epidemiology genetics MeSH
- Young Adult MeSH
- Biomarkers, Tumor blood metabolism MeSH
- Follow-Up Studies MeSH
- Graft vs Host Disease diagnosis epidemiology MeSH
- Disease-Free Survival MeSH
- Prognosis MeSH
- WT1 Proteins blood metabolism MeSH
- Gene Expression Regulation, Leukemic MeSH
- Neoplasm, Residual MeSH
- Risk Factors MeSH
- Aged MeSH
- Gene Expression Profiling MeSH
- Feasibility Studies MeSH
- Severity of Illness Index MeSH
- Hematopoietic Stem Cell Transplantation adverse effects MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: This work summarizes our experience with WT1 monitoring before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT). PATIENTS AND METHODS: The expression of WT1 gene was measured by real-time polymerase chain reaction in peripheral blood according to the European Leukemia Net recommendations. Between May 2005 and August 2019, we analyzed 147 consecutive patients with acute myeloid leukemia with high WT1 expression at diagnosis, transplanted in first (CR1) or second (CR2) complete remission. RESULTS: At the time of allo-HSCT, 107 patients had WT1-normal expression (WT1 ≤ 50 copies), and 40 patients had WT1-high expression. The median follow-up was 21 months. The estimated 5-year overall survival and event-free survival was significantly better in the WT1-normal cohort (65% and 57% vs. 37% and 25%; P = .0003 and P < .0001, respectively) and 5-year cumulative incidence of relapse was significantly lower in the WT1-normal group (19% vs. 53%; P < .0001). Five-year non-relapse mortality was not significantly different (20% and 23%). Multivariate analysis revealed WT1-high expression and acute graft-versus-host disease grade 3/4 as significantly negative prognostic factors for OS. Overall, 49 patients developed WT1 molecular relapse in the post-transplant period; in 14 cases, the therapeutic intervention was done. In all but 1 relapsed patient where WT1 minimal residual disease (MRD) was monitored (38 patients), we detected WT1-high levels (sensitivity of 97%). CONCLUSION: The results of the analysis confirmed our previous experience that WT1 status before allo-HSCT is a strong prognostic factor for both OS and relapse risk. In addition, we confirmed the usefulness of this marker for MRD monitoring after allo-HSCT. The main advantage is the possibility of frequent MRD monitoring in peripheral blood and early bone marrow examination based on WT1-high expression.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004639
- 003
- CZ-PrNML
- 005
- 20220127145109.0
- 007
- ta
- 008
- 220113s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clml.2020.09.008 $2 doi
- 035 __
- $a (PubMed)33160932
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Valkova, Veronika $u Department of Bone Marrow Transplant, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: veronika.valkova@uhkt.cz
- 245 10
- $a WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience / $c V. Valkova, J. Vydra, M. Markova, E. Cerovska, M. Vrana, I. Marinov, H. Cechova, P. Cetkovsky, A. Vitek, C. Salek
- 520 9_
- $a BACKGROUND: This work summarizes our experience with WT1 monitoring before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT). PATIENTS AND METHODS: The expression of WT1 gene was measured by real-time polymerase chain reaction in peripheral blood according to the European Leukemia Net recommendations. Between May 2005 and August 2019, we analyzed 147 consecutive patients with acute myeloid leukemia with high WT1 expression at diagnosis, transplanted in first (CR1) or second (CR2) complete remission. RESULTS: At the time of allo-HSCT, 107 patients had WT1-normal expression (WT1 ≤ 50 copies), and 40 patients had WT1-high expression. The median follow-up was 21 months. The estimated 5-year overall survival and event-free survival was significantly better in the WT1-normal cohort (65% and 57% vs. 37% and 25%; P = .0003 and P < .0001, respectively) and 5-year cumulative incidence of relapse was significantly lower in the WT1-normal group (19% vs. 53%; P < .0001). Five-year non-relapse mortality was not significantly different (20% and 23%). Multivariate analysis revealed WT1-high expression and acute graft-versus-host disease grade 3/4 as significantly negative prognostic factors for OS. Overall, 49 patients developed WT1 molecular relapse in the post-transplant period; in 14 cases, the therapeutic intervention was done. In all but 1 relapsed patient where WT1 minimal residual disease (MRD) was monitored (38 patients), we detected WT1-high levels (sensitivity of 97%). CONCLUSION: The results of the analysis confirmed our previous experience that WT1 status before allo-HSCT is a strong prognostic factor for both OS and relapse risk. In addition, we confirmed the usefulness of this marker for MRD monitoring after allo-HSCT. The main advantage is the possibility of frequent MRD monitoring in peripheral blood and early bone marrow examination based on WT1-high expression.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádorové biomarkery $x krev $x metabolismus $7 D014408
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a studie proveditelnosti $7 D005240
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a regulace genové exprese u leukemie $7 D015973
- 650 _2
- $a nemoc štěpu proti hostiteli $x diagnóza $x epidemiologie $7 D006086
- 650 _2
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a akutní myeloidní leukemie $x krev $x genetika $x mortalita $x terapie $7 D015470
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $x epidemiologie $x genetika $7 D009364
- 650 _2
- $a reziduální nádor $7 D018365
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a hodnocení rizik $x metody $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a proteiny WT1 $x krev $x metabolismus $7 D025721
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vydra, Jan $u Department of Bone Marrow Transplant, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Markova, Marketa $u Department of Bone Marrow Transplant, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Cerovska, Ela $u Department of Bone Marrow Transplant, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Vrana, Milena $u Department of Bone Marrow Transplant, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Marinov, Iuri $u Department of Bone Marrow Transplant, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Cechova, Hana $u Department of Bone Marrow Transplant, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Cetkovsky, Petr $u Department of Bone Marrow Transplant, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Vitek, Antonin $u Department of Bone Marrow Transplant, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Salek, Cyril $u Department of Bone Marrow Transplant, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 21, č. 2 (2021), s. e145-e151
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33160932 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145106 $b ABA008
- 999 __
- $a ok $b bmc $g 1751947 $s 1155788
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 21 $c 2 $d e145-e151 $e 20201012 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
- LZP __
- $a Pubmed-20220113
